Inhibition of BTK disrupts signaling downstream of the B-cell receptor (BCR), a pathway on which the survival of CLL cells is dependent (Honigberg et al., 2010; Herman et al., 2011). The gene discussed is BCR; the disease is B-cell chronic lymphocytic leukemia.